We’re discovering and delivering innovative medicines that help solve serious health issues to have a remarkable impact on people’s lives.
We are AbbVie, a highly focused, research-driven biopharmaceutical company.

With employees in more than 70 countries around the world, we are dedicated to developing and delivering a consistent stream of innovative new medicines with distinct and compelling patient benefits.

We are a passionate, diverse and inclusive organization with a culture that supports the best ideas, wherever they originate. Our scientists are shaping their fields and inspire us to do all we can to bring medicines to patients quickly and safely. With a focus on leadership, development and performance, we are proud to have been recognized around the world as a great place to work and a top science employer.

As we all face the coronavirus pandemic crisis around the world, we have a new perspective as we look back at 2019 as an organization. We believe that impact goes beyond medicine, which is why we also provide broader support to our patients, operate responsibly and actively engage in the communities where we live and work. In response to the pandemic, we committed $35 million to COVID-19 relief efforts in March 2020 and will continue to partner with global health authorities and institutions on clinical research. AbbVie is focused on the health and safety of our employees, patients and health care providers and will continue to provide updates on our response at abbvie.com/coronavirus.

With this strong foundation and the potential for AbbVie’s future, we also plan to complete our acquisition of Allergan in Q2 of 2020, our largest acquisition to date. The impact this has on our broader business will be reflected in our lookback next year.

This report highlights the impact of our efforts in 2019.

**Our Focus**

With leading scientific and industry capabilities, a comprehensive approach to tackling the toughest health care challenges and a track record of achievement, we are a long-term partner in the pursuit of better health outcomes.

**In 2019, we focused on these primary therapeutic areas:**

- **Immunology**
- **Oncology**
- **Neuroscience**
- **Virology**
- **Women’s Health**

In more than 70 countries, AbbVie employees are working every day to advance health solutions for people around the world.

We have more than 30,000 employees globally and products are sold in 175+ countries.

**Workplace & Diversity**

- DiversityInc “Top 50 Companies for Diversity”
- FORTUNE “100 Best Companies to Work For”
- Great Place to Work “World’s Best Workplaces”
- Human Rights Campaign Corporate Equality Index
- Science Magazine’s Top Employers
- Working Mother “100 Best Companies”

**Environment, Social and Governance**

- Dow Jones Sustainability World Index
- EcoVadis Corporate Social Responsibility Assessment Gold Medal
- FTSE4Good Index
- S&P 500 ESG Index

**Citizenship**

- Civic 50
- Corporate Responsibility Magazine’s “100 Best Corporate Citizens”
- FORTUNE/Great Place to Work “Best Workplaces for Giving Back”
- PEOPLE’s “50 Companies That Care”

**Business Performance**

- FORTUNE 100
- FORTUNE World’s Most Admired Companies
- IDEA Pharma Innovation Index
- Pharma Replist Most Reputable Companies

**Through the work that we do, AbbVie has been recognized by organizations around the world in addition to more than 40 great workplace and diversity and inclusion lists.**
We tackle areas of great need today, while preparing for those of the future.

We leverage more than 130 years of innovation with therapies in 33 disease areas, while continuing to invest in the discovery and development of new medicines for a healthier world.

52m+
patients treated by AbbVie’s medicines every year

13m+
patients in the United States

“They’re dedicating their lives and their science to making the world a better place. If I were to meet the AbbVie scientists, I would just hug them.”
– Jennifer, Chronic lymphocytic leukemia patient

1.3b+
people globally

188m+
potential patients in the United States

We’re studying compounds that have potential to treat

284
AbbVie patient support programs globally

86
support programs in the U.S.

We discover and deliver medicines that make a remarkable impact on patients right now.

175+
countries where our products help patients

33
conditions treated across infant, adolescent, adult and senior stages of life

AbbVie is committed to understanding the patient experience across countries and conditions to reduce barriers to treatment and avoidable health care spending.

“Proactively supporting patients through AbbVie programs

I was able to use the AbbVie patient assistance program, which was a blessing.”
– Don, Hepatitis C patient

Access to medicine

In 2019, we brought two new products to the immunology community. We continue to build on our commitment to further the care of people living with immune-mediated conditions.

More than a decade ago, we accepted the challenge of developing a new medicine that could elevate rheumatoid arthritis (RA) treatment expectations. Now, we offer an expanded immunology portfolio to provide patients and physicians with additional options to help meet peoples’ evolving needs.

In 2019, we brought two new products to the immunology community. We continue to build on our commitment to further the care of people living with immune-mediated conditions.

More than a decade ago, we accepted the challenge of developing a new medicine that could elevate rheumatoid arthritis (RA) treatment expectations. Now, we offer an expanded immunology portfolio to provide patients and physicians with additional options to help meet peoples’ evolving needs.

We support independent education programs for patients, caregivers and health care providers.

584k+
health care professionals reached through independent medical education grants

415k+
patients reached through patient education grants

We leverage more than 130 years of innovation with therapies in 33 disease areas, while continuing to invest in the discovery and development of new medicines for a healthier world.

We’re studying compounds that have potential to treat

284
AbbVie patient support programs globally

86
support programs in the U.S.

We discover and deliver medicines that make a remarkable impact on patients right now.

175+
countries where our products help patients

33
conditions treated across infant, adolescent, adult and senior stages of life

AbbVie is committed to understanding the patient experience across countries and conditions to reduce barriers to treatment and avoidable health care spending.

“Proactively supporting patients through AbbVie programs

I was able to use the AbbVie patient assistance program, which was a blessing.”
– Don, Hepatitis C patient

Access to medicine

In 2019, we brought two new products to the immunology community. We continue to build on our commitment to further the care of people living with immune-mediated conditions.

More than a decade ago, we accepted the challenge of developing a new medicine that could elevate rheumatoid arthritis (RA) treatment expectations. Now, we offer an expanded immunology portfolio to provide patients and physicians with additional options to help meet peoples’ evolving needs.

In 2019, we brought two new products to the immunology community. We continue to build on our commitment to further the care of people living with immune-mediated conditions.

More than a decade ago, we accepted the challenge of developing a new medicine that could elevate rheumatoid arthritis (RA) treatment expectations. Now, we offer an expanded immunology portfolio to provide patients and physicians with additional options to help meet peoples’ evolving needs.

We support independent education programs for patients, caregivers and health care providers.

584k+
health care professionals reached through independent medical education grants

415k+
patients reached through patient education grants
We take smart risks when the stakes are high.

We are courageous in the face of tough decisions and learn from failures that are inevitable in the scientific process.

Investing $5b* to advance science

It takes unwavering commitment and confidence to bring solutions from the petri dish to patients. AbbVie invested $5 billion in researching new medicines in 2019. We do this to discover and test compounds with the potential to treat more than 1.3 billion people across the globe including nearly 188 million in the United States.

Innovation that starts in our labs

By harnessing years of expertise in immunology research, a cross-functional team collaborated for more than a decade to identify an optimal candidate for treatment of moderate to severe RA. In the process they screened more than 2,500 compounds before selecting a compound for full development. The team also pioneered innovative methods in medicinal chemistry and even invented some of the systems needed to test their hypotheses. In 2019, the compound the team discovered over a decade ago received regulatory approval.

Some of the tough diseases we’re tackling:
- Alzheimer’s disease
- Cancer
- Parkinson’s disease
- Multiple sclerosis
- Crohn’s disease
- Atopic dermatitis
- Uterine fibroids
- Rheumatoid arthritis (RA)
- Hepatitis C

Driving innovation, together

AbbVie partners with more than 220 leading biotechs, universities, nonprofits, and government organizations to collaborate and advance science every year.

IDEA Pharma’s Productive Innovation Index
AbbVie ranked second on the index which ranks pharmaceutical companies based on their ability to create inventions with meaningful value.

Advancing scientific knowledge every day

Our scientists in the medical research community published 1,150 papers in 2019 — allowing others to build on scientific knowledge we developed. We’re also constantly looking for great ideas outside our own walls. Consistent with our long-term strategy and large investment in R&D, we have a number of programs in mid- and late-stage development and continue to make significant pipeline advancements.

AbbVie has a robust pipeline

64k+ patients participated in clinical trials in 2019

61 countries

10k+ sites

72% of medicines in our pipeline are considered first-in-kind

“Everyone at AbbVie has one goal. And that’s to take care of patients.”
– Charlotte Owens, MD
Medical Director, General Medicine and Virology
Impact on societies

We’re a long-term partner in the pursuit of health and well-being.

We take our part in the global community seriously by supporting the patients we serve, the people we employ and the world we live in.

Supporting our employees and their families in times of need

In 2019, we formalized our programs to support employees when they need it most. The AbbVie Employee Assistance Fund programs offer employees around the world assistance at two pivotal moments: when a child goes to college and when disaster strikes.

It’s part of AbbVie’s ongoing commitment to support our employees who come to work every day to make a remarkable impact on patients’ lives.

AbbVie is committed to environmental stewardship.

We have continued to make progress on our absolute environmental sustainability targets relative to our 2015 baseline, even as our business has grown. We’re working to reduce carbon emissions through investment in technology, infrastructure and processes that will be more energy efficient.

24% of our purchased electricity in 2019 came from renewable sources, up from 9% in 2016 and almost halfway to our 2025 target of 50%.

Ten new environmental sustainability projects were approved through our SPARK innovation accelerator, an incubator for employee-driven sustainability proposals.

The Week of Possibilities is our global week of volunteerism uniting AbbVie employees around the world with a single purpose: to give back to our local communities.

40,474
volunteer hours

167
community partners and 290 projects

70k
children inspired

70
schools and community centers updated

50k
people benefitting from the improvement of local community centers

8.3k+
volunteers

300+
scholarships awarded

50+
countries

8.3k+
volunteers

170
locations

In the inaugural year of the program, over 300 scholarships were awarded to children of AbbVie employees from 25 countries.

In its first year, the program provided financial assistance to employees from over 12 countries facing large-scale or individual disasters, ranging from evacuation to the loss of a loved one.

Impact on societies

40,474
volunteer hours

167
community partners and 290 projects

70k
children inspired

70
schools and community centers updated

50k
people benefitting from the improvement of local community centers

8.3k+
volunteers

300+
scholarships awarded

50+
countries

8.3k+
volunteers

170
locations

In the inaugural year of the program, over 300 scholarships were awarded to children of AbbVie employees from 25 countries.

In its first year, the program provided financial assistance to employees from over 12 countries facing large-scale or individual disasters, ranging from evacuation to the loss of a loved one.
We invest in people and the culture that drive breakthroughs.

AbbVie is an economic multiplier. With more than 30,000 employees globally, our total impact on employment is more than five times that amount through direct and indirect business activity.

Each job at AbbVie creates opportunity for others.

The jobs we create pay well and attract a workforce with diverse skills and educations, including Ph.D. research scientists, laboratory technicians, support staff and more, who live, work, and spend money in their local communities. We also spend millions of dollars each year with suppliers purchasing goods and services. This all provides benefits for third-party suppliers and local economies in the form of higher sales, tax revenue, and economic development.

“Every day that we spend at work is actually helping people.”
– Maurizio Facheris, MD
Medical Director, Neuroscience Development

We treat everyone equally, with dignity and respect. Around the world, our employees embrace diverse backgrounds and perspectives, which allows us all to achieve our best.

53%
of our workforce are women

32%
of our US workforce is from an under-represented population

48%
of management-level employees are women

AbbVie has a large presence around the world.

<table>
<thead>
<tr>
<th>Research and Development Centers</th>
<th>Manufacturing Facilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>14</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Employees in Puerto Rico</th>
<th>Employees in Germany</th>
<th>Employees in Italy</th>
<th>Employees in Japan</th>
</tr>
</thead>
<tbody>
<tr>
<td>~1.1k</td>
<td>~2.6k</td>
<td>~1.5k</td>
<td>~1.2k</td>
</tr>
</tbody>
</table>

AbbVie has a presence in all 50 states

Our largest employee base globally is in Illinois where our global headquarters is located.

<table>
<thead>
<tr>
<th>Employees in California</th>
<th>Employees in Illinois</th>
<th>Employees in Massachusetts</th>
</tr>
</thead>
<tbody>
<tr>
<td>~1.3k</td>
<td>~9.4k</td>
<td>~1k</td>
</tr>
</tbody>
</table>

AbbVie creates jobs & stimulates economic activity.

In 2019, AbbVie spent more than $13.8 billion with more than 48,000 third-party suppliers across 754 industries. AbbVie creates opportunities and growth to support the discovery, development, and distribution of new medicines. This investment includes diverse suppliers: AbbVie spent more than $900,000,000 with nearly 2,000 U.S. small and diverse-owned businesses in 2019.

Suppliers in:

<table>
<thead>
<tr>
<th>Countries and All 50 States Plus Washington, DC and Puerto Rico</th>
<th>Suppliers Globally</th>
<th>Spent with Third Parties Globally</th>
<th>Spent with Third Parties in the U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>121</td>
<td>48k+</td>
<td>$13.8b</td>
<td>$9.2b</td>
</tr>
</tbody>
</table>